Document is current
Any future updates will be listed below
-
Authors
Vandervorst, Fenne
Van Deun, Laura
Van Dycke, Annelies
Paemeleire, Koen
Reuter, Uwe
Schoenen, Jean
Versijpt, Jan https://orcid.org/0000-0002-8710-5715
- License Information
-
More Information
Article History
Received: 13 July 2021
Accepted: 24 September 2021
First Online: 25 October 2021
Change Date: 12 November 2021
Change Type: Update
Change Details: The formatting of Tables 1-3 have been updated.
Declarations
:
: Not applicable.
: Not applicable.
: KP has received personal compensation from Allergan, Amgen/Novartis, Eli Lilly, Lundbeck and Teva for consulting, serving on a scientific advisory board, and/or speaking and is a clinical trial investigator for Amgen/Novartis (erenumab), Eli Lilly (galcanezumab), and Autonomic Technologies Inc. (sphenopalatine ganglion stimulation). UR received consulting fees, speaking/teaching fees, and/or research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, Eli Lilly, Medscape, Novartis, StreamMedUp and Teva Pharmaceuticals. JS has received personal compensation from Allergan, Amgen/Novartis, Eli Lilly, Lundbeck,Teva, Cefaly Technology, Autonomic Technologies Inc. and Man & Science for consulting, serving on a scientific advisory board, and/or speaking and is an investigator for Eli Lilly, Novartis, Lundbeck and Teva. JV received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan.
